Spero Therapeutics’ (NASDAQ:SPRO) quiet period is set to expire on Tuesday, December 12th. Spero Therapeutics had issued 5,500,000 shares in its initial public offering on November 2nd. The total size of the offering was $77,000,000 based on an initial share price of $14.00. During Spero Therapeutics’ quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

A number of research analysts have recently issued reports on the company. Bank of America initiated coverage on Spero Therapeutics in a research note on Monday, November 27th. They set a “neutral” rating on the stock. Stifel Nicolaus initiated coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $26.00 target price on the stock. Cowen initiated coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued an “outperform” rating on the stock. Finally, Oppenheimer initiated coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $30.00 target price on the stock.

Shares of Spero Therapeutics (NASDAQ:SPRO) opened at $12.28 on Tuesday. Spero Therapeutics has a 12 month low of $10.83 and a 12 month high of $15.40.

In other Spero Therapeutics news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Casper Breum bought 214,285 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $2,999,990.00. The disclosure for this purchase can be found here. Insiders purchased 649,356 shares of company stock worth $9,090,984 over the last three months.

TRADEMARK VIOLATION NOTICE: “Spero Therapeutics, Inc.’s Quiet Period To Expire on December 12th (NASDAQ:SPRO)” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/05/spero-therapeutics-inc-s-quiet-period-to-expire-on-december-12th-nasdaqspro.html.

About Spero Therapeutics

SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.

Receive News & Ratings for Spero Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.